Reported results
- Q3 2026 total revenues were $101.9 million, representing a 24% increase compared to Q3 2025.
- Q3 2026 commercial product revenue was $45.0 million, representing a 102% increase compared to Q3 2025.
- GAAP reported net loss was $23,224 thousand (or $(0.07) per basic and diluted share) for the three months ended September 30, 2026.
- Non-GAAP adjusted net loss was $3,615 thousand (or $(0.01) per basic share) for the three months ended September 30, 2026.
- Furoscix generated $22.4 million in net revenue for the third quarter of 2026.
- Afrezza generated $19.3 million in net sales for the third quarter of 2026.
Price and volatility reaction
The stock moved +3.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -23.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 3.76 | 2026-11-05 |
| Close after release | 3.9 | 2026-11-06 |
| Realised move | +3.7% | close to close |
| 30d ATM IV change | -23.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
